Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; Department of Health Services Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Massachusetts General Physicians Organization, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gynecol Oncol. 2019 Mar;152(3):587-593. doi: 10.1016/j.ygyno.2018.12.013. Epub 2018 Dec 19.
Identify the major factors that drive standardized cost in providing surgical care for women with ovarian cancer, characterize the magnitude of variation in resource utilization between centers, and to investigate the relationship between resource utilization and quality of care provided.
Retrospective cohort study of hospitals across the United States reporting to the Premier Database who cared for patients with ovarian cancer diagnosed between 2007 and 2014. The primary outcome was standardized total cost of the index hospitalization. To assess the relationship between hospital standardized costs and patient outcomes, we identified four measures of quality: 1) complications, 2) re-operation, 3) length of stay > 15 days, and 4) unplanned readmission.
The study population included 15,857 patients treated at 226 hospitals. The median standardized cost for hospitalizations was $13,267 (IQR = $3342). Reoperation was associated with 49% increase (95% CI = 43%-56%), and having minor complication was associated with 10% (95% CI = 8%-12%) increase in standardized cost, a moderate complication was associated with 36% (95% CI = 33%-38%) increase, and a major complication was associated with 83% (95% CI = 76%-89%) increase. The average risk-adjusted hospital standardized costs for hospitals in the highest resource use quartiles was 56% higher than the average hospital costs for hospitals in the lowest quartile ($10,826 vs. $16,933). The largest variation was in operating room standardized cost (45.5% of the total variation in operating room cost is explained by differences in hospital practices) and supplies (41.7%).
We identified significant variation in standardized costs among women who underwent surgery for ovarian cancer, operating room and supply costs are the largest drivers of variation.
确定为卵巢癌女性提供外科护理的标准化成本的主要驱动因素,描述各中心之间资源利用的差异程度,并研究资源利用与提供的护理质量之间的关系。
对向 Premier 数据库报告的美国各地医院进行回顾性队列研究,这些医院在 2007 年至 2014 年间收治了卵巢癌患者。主要结果是指数住院的标准化总成本。为了评估医院标准化成本与患者结果之间的关系,我们确定了四项质量指标:1)并发症,2)再次手术,3)住院时间超过 15 天,以及 4)计划外再入院。
研究人群包括在 226 家医院接受治疗的 15857 名患者。住院的中位数标准化成本为 13267 美元(IQR = 3342 美元)。再次手术与 49%的成本增加相关(95%CI = 43%-56%),轻微并发症与 10%的标准化成本增加相关(95%CI = 8%-12%),中度并发症与 36%的成本增加相关(95%CI = 33%-38%),严重并发症与 83%的成本增加相关(95%CI = 76%-89%)。资源使用量最高的四分位医院的平均风险调整后医院标准化成本比资源使用量最低的四分位医院的平均医院成本高 56%($10826 比$16933)。最大的差异是手术室标准化成本(手术室成本总变异的 45.5%由医院实践的差异解释)和供应品(41.7%)。
我们发现卵巢癌女性接受手术治疗的标准化成本存在显著差异,手术室和供应成本是差异的最大驱动因素。